Literature DB >> 12239335

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Miguel E Quiñones-Mateu1, Mahlet Tadele, Mariona Parera, Antonio Mas, Jan Weber, Héctor R Rangel, Bikram Chakraborty, Bonaventura Clotet, Esteban Domingo, Luis Menéndez-Arias, Miguel A Martínez.   

Abstract

Recent studies have shown that the accumulation of multiple mutations associated with nucleoside reverse transcriptase inhibitor (NRTI) resistance may be grouped as multi-NRTI resistance (MNR) complexes. In this study, we have examined the viral fitness of recombinant viruses carrying the reverse transcriptase (RT) of a human immunodeficiency virus type 1 (HIV-1) primary isolate harboring mutations comprising the MNR 69 insertion complex. Different RT mutants were prepared in the sequence context of either the wild-type RT sequence of the HIV-1(BH10) isolate or the sequence found in a clinical HIV-1 isolate with the MNR 69 insertion mutation. As expected, in the presence of zidovudine, recombinant viruses harboring the MNR RT from the patient were more fit than wild-type viruses. However, in the absence of drug, the virus with the RT from the original clinical isolate (SS) was more fit than (i) the wild-type virus with an engineered serine insertion between residues 69 and 70 (T69SSS) and (ii) the recombinant virus with the MNR RT where the insertion was removed (2S0S). These results suggest that RT insertions, in the right sequence context (i.e., additional mutations contained in the MNR 69 insertion complex), enhance NRTI resistance and may improve viral fitness. Thus, comparing complex mutation patterns with viral fitness may help to elucidate the role of uncharacterized drug resistance mutations in antiretroviral treatment failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239335      PMCID: PMC136580          DOI: 10.1128/jvi.76.20.10546-10552.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations.

Authors:  C Tamalet; N Yahi; C Tourrès; P Colson; A M Quinson; I Poizot-Martin; C Dhiver; J Fantini
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

Review 2.  Multi-drug resistant HIV-1.

Authors:  A S Omrani; D Pillay
Journal:  J Infect       Date:  2000-07       Impact factor: 6.072

3.  Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.

Authors:  H M Precious; H F Günthard; J K Wong; R T D'Aquila; V A Johnson; D R Kuritzkes; D D Richman; A J Leigh Brown
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

4.  Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain.

Authors:  C Briones; V Soriano
Journal:  Antivir Ther       Date:  1999

5.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Authors:  S J Little; E S Daar; R T D'Aquila; P H Keiser; E Connick; J M Whitcomb; N S Hellmann; C J Petropoulos; L Sutton; J A Pitt; E S Rosenberg; R A Koup; B D Walker; D D Richman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

6.  The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.

Authors:  L Ross; M Johnson; N Graham; M Shaefer; M St Clair
Journal:  J Hum Virol       Date:  1999 Sep-Oct

7.  Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.

Authors:  K Van Vaerenbergh; K Van Laethem; J Albert; C A Boucher; B Clotet; M Floridia; J Gerstoft; B Hejdeman; C Nielsen; C Pannecouque; L Perrin; M F Pirillo; L Ruiz; J C Schmit; F Schneider; A Schoolmeester; R Schuurman; H J Stellbrink; L Stuyver; J Van Lunzen; B Van Remoortel; E Van Wijngaerden; S Vella; M Witvrouw; S Yerly; E De Clercq; J Destmyer; A M Vandamme
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.

Authors:  A Rakik; M Ait-Khaled; P Griffin; T A Thomas; M Tisdale; J P Kleim
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

9.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

10.  Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure.

Authors:  C Balotta; M Violin; L Monno; P Bagnarelli; C Riva; G Facchi; A Berlusconi; M Lippi; S Rusconi; M Clementi; M Galli; G Angarano; M Moroni
Journal:  J Acquir Immune Defic Syndr       Date:  2000-07-01       Impact factor: 3.731

View more
  16 in total

1.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 2.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Immune-mediated attenuation of HIV-1.

Authors:  Denis R Chopera; Jaclyn K Wright; Mark A Brockman; Zabrina L Brumme
Journal:  Future Virol       Date:  2011-08       Impact factor: 1.831

4.  Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.

Authors:  Lia van der Hoek; Nicole Back; Maarten F Jebbink; Anthony de Ronde; Margreet Bakker; Suzanne Jurriaans; Peter Reiss; Neil Parkin; Ben Berkhout
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.

Authors:  Stefania Paolucci; Fausto Baldanti; Giovanni Maga; Reynel Cancio; Maurizio Zazzi; Maurizio Zavattoni; Antonella Chiesa; Silvio Spadari; Giuseppe Gerna
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.

Authors:  Peter R Meyer; Johan Lennerstrand; Suzanne E Matsuura; Brendan A Larder; Walter A Scott
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  HIV-1 Fitness and Replication Capacity: What Are They and Can They Help in Patient Management?

Authors:  Frank Maldarelli
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

Review 10.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.